1. bookVolumen 14 (2021): Heft 1 (June 2021)
Zeitschriftendaten
License
Format
Zeitschrift
eISSN
1313-9053
Erstveröffentlichung
08 Sep 2014
Erscheinungsweise
2 Hefte pro Jahr
Sprachen
Englisch
Uneingeschränkter Zugang

A Study on Tumor-Infiltrating Lymphocytes in Different Subtypes of Breast Cancer

Online veröffentlicht: 12 Jul 2021
Volumen & Heft: Volumen 14 (2021) - Heft 1 (June 2021)
Seitenbereich: 70 - 81
Eingereicht: 15 Jan 2021
Akzeptiert: 22 Apr 2021
Zeitschriftendaten
License
Format
Zeitschrift
eISSN
1313-9053
Erstveröffentlichung
08 Sep 2014
Erscheinungsweise
2 Hefte pro Jahr
Sprachen
Englisch

1. Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol. 2015;26(2):259-71.10.1093/annonc/mdu450626786325214542 Search in Google Scholar

2. Rathore AS, Kumar S, Konwar R, Makker A, Negi MP, Goel MM. CD3+, CD4+ & CD8+ tumour infiltrating lymphocytes (TILs) are predictors of favourable survival outcome in infiltrating ductal carcinoma of breast. Indian J Med Res. 2014;140(3):361-9. Search in Google Scholar

3. Rathore AS, Goel MM, Makker A, Kumar S, Srivastava AN. Prognostic Impact of CD3 Tumor Infiltrating Lymphocytes in Triple-negative Breast Cancer. Indian Journal of Clinical Practice. 2013; 24(4): 376-80. Search in Google Scholar

4. Loi S. Host antitumor immunity plays a role in the survival of patients with newly diagnosed triple-negative breast cancer. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2014;32(27):2935-7.10.1200/JCO.2014.56.767725071115 Search in Google Scholar

5. Lee S, Cho EY, Park YH, Ahn JS, Im YH. Prognostic impact of FOXP3 expression in triple-negative breast cancer. Acta Oncol. 2013;52(1):73-81.10.3109/0284186X.2012.73152023075422 Search in Google Scholar

6. Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, van de Vijver MJ. WHO Classification of Tumours of the Breast. 4th Edition. Lyon: IARC Press; 2012. 240p. Search in Google Scholar

7. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991;19(5):403-10.10.1111/j.1365-2559.1991.tb00229.x1757079 Search in Google Scholar

8. 8. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, editors. AJCC cancer staging manual (7th ed). New York, NY: Springer; 2010. Search in Google Scholar

9. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010;28(16):2784-95.10.1200/JCO.2009.25.6529288185520404251 Search in Google Scholar

10. Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013;31(31):3997-4013.10.1200/JCO.2013.50.998424101045 Search in Google Scholar

11. Dowsett M, Nielsen TO, A’Hern R, Bartlett J, Coombes RC, Cuzick J, et al. International Ki-67 in Breast Cancer Working Group. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst. 2011;103(22):1656-64.10.1093/jnci/djr393321696721960707 Search in Google Scholar

12. Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thürlimann B, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol. 2013;24(9):2206-23.10.1093/annonc/mdt303375533423917950 Search in Google Scholar

13. Kos Z, Roblin E, Kim RS, Michiels S, Gallas BD, Chen W, et al. International Immuno-Oncology Biomarker Working Group. Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer. NPJ Breast Cancer. 2020;6:17.10.1038/s41523-020-0156-0721786332411819 Search in Google Scholar

14. Amgad M, Stovgaard ES, Balslev E, Thagaard J, Chen W, Dudgeon S, et al. International Immuno-Oncology Biomarker Working Group. Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group. NPJ Breast Cancer. 2020;6:16.10.1038/s41523-020-0154-2721782432411818 Search in Google Scholar

15. Klauschen F, Müller KR, Binder A, Bockmayr M, Hägele M, Seegerer P, et al. International Immuno-Oncology Biomarker Working Group. Scoring of tumor-infiltrating lymphocytes: From visual estimation to machine learning. Semin Cancer Biol. 2018;52(2):151-7.10.1016/j.semcancer.2018.07.00129990622 Search in Google Scholar

16. Wein L, Savas P, Luen SJ, Virassamy B, Salgado R, Loi S. Clinical Validity and Utility of Tumor-Infiltrating Lymphocytes in Routine Clinical Practice for Breast Cancer Patients: Current and Future Directions. Front Oncol. 2017;7:156.10.3389/fonc.2017.00156554094228824872 Search in Google Scholar

17. Dieci MV, Radosevic-Robin N, Fineberg S, van den Eynden G, Ternes N, Penault-Llorca F, et al. International Immuno-Oncology Biomarker Working Group on Breast Cancer. Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer. Semin Cancer Biol. 2018;52(2):16-25.10.1016/j.semcancer.2017.10.00329024776 Search in Google Scholar

18. Eckstein M, Erben P, Kriegmair MC, Worst TS, Weiß CA, Wirtz RM, et al. Performance of the Food and Drug Administration/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumab. Eur J Cancer. 2019;106:234-43.10.1016/j.ejca.2018.11.00730528808 Search in Google Scholar

19. Gravara LD, Battiloro C, Cantile R, Letizia A, Vitiello F, Montesarchio V, et al. Chemotherapy and/or immune checkpoint inhibitors in NSCLC first-line setting: what is the best approach? Lung Cancer Manag. 2020;9(1):LMT22.10.2217/lmt-2019-0018711057132256708 Search in Google Scholar

20. Mao Y, Qu Q, Zhang Y, Liu J, Chen X, Shen K. The value of tumor infiltrating lymphocytes (TILs) for predicting response to neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis. PLoS One. 2014;9(12):e115103.10.1371/journal.pone.0115103426487025501357 Search in Google Scholar

21. Loi S. Tumor-infiltrating lymphocytes, breast cancer subtypes and therapeutic efficacy. Oncoimmunology. 2013;2(7):e24720.10.4161/onci.24720378200924073365 Search in Google Scholar

22. Criscitiello C, Esposito A, Gelao L, Fumagalli L, Locatelli M, Minchella I, et al. Immune approaches to the treatment of breast cancer, around the corner? Breast Cancer Res. 2014;16(1):204.10.1186/bcr3620397844225774617 Search in Google Scholar

23. Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, et al. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N Engl J Med. 2018;379(22):2108-21.10.1056/NEJMoa180961530345906 Search in Google Scholar

24. Helal TE, Ibrahim EA, Alloub AI. Immunohistochemical analysis of tumor-infiltrating lymphocytes in breast carcinoma: relation to prognostic variables. Indian J Pathol Microbiol. 2013;56(2):89-93.10.4103/0377-4929.11867624056641 Search in Google Scholar

25. Shou J, Zhang Z, Lai Y, Chen Z, Huang J. Worse outcome in breast cancer with higher tumor-infiltrating FOXP3+ Tregs : a systematic review and meta-analysis. BMC Cancer. 2016;16(1):687.10.1186/s12885-016-2732-0500219027566250 Search in Google Scholar

26. Gao G, Wang Z, Qu X, Zhang Z. Prognostic value of tumor-infiltrating lymphocytes in patients with triple-negative breast cancer: a systematic review and meta-analysis. BMC Cancer. 2020;20(1):179.10.1186/s12885-020-6668-z705766232131780 Search in Google Scholar

27. Ahn S, Chung YR, Seo AN, Kim M, Woo JW, Park SY. Changes and prognostic values of tumor-infiltrating lymphocyte subsets after primary systemic therapy in breast cancer. PLoS One. 2020;15(5):e0233037.10.1371/journal.pone.0233037721977932401825 Search in Google Scholar

28. Giraldo NA, Becht E, Vano Y, Sautès-Fridman C, Fridman WH. The immune response in cancer: from immunology to pathology to immunotherapy. Virchows Arch. 2015;467(2):127-35.10.1007/s00428-015-1787-726077464 Search in Google Scholar

29. Ohtani H, Mori-Shiraishi K, Nakajima M, Ueki H. Defining lymphocyte-predominant breast cancer by the proportion of lymphocyte-rich stroma and its significance in routine histopathological diagnosis. Pathol Int. 2015;65(12):644-51.10.1111/pin.12355473840326530981 Search in Google Scholar

30. García-Teijido P, Cabal ML, Fernández IP, Pérez YF. Tumor-Infiltrating Lymphocytes in Triple Negative Breast Cancer: The Future of Immune Targeting. Clin Med Insights Oncol. 2016;10(Suppl 1):31-9.10.4137/CMO.S34540482272227081325 Search in Google Scholar

31. Hudeček J, Voorwerk L, van Seijen M, Nederlof I, de Maaker M, van den Berg J, et al. International Immuno-Oncology Biomarker Working Group. Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials. NPJ Breast Cancer. 2020;6:15.10.1038/s41523-020-0155-1721794132436923 Search in Google Scholar

32. Burstein HJ, Curigliano G, Loibl S, Dubsky P, Gnant M, Poortmans P, et al. Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019. Ann Oncol. 2019;30(10):1541-57.10.1093/annonc/mdz23531373601 Search in Google Scholar

33. WHO classification of tumours editorial board. Breast Tumours. (WHO classification of tumours series, 5th ed., vol. 2) (International Agency for Research on Cancer, Lyon, France, 2019). Search in Google Scholar

34. Miyashita M, Sasano H, Tamaki K, Hirakawa H, Takahashi Y, Nakagawa S, et al. Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study. Breast Cancer Res. 2015;17(1):124.10.1186/s13058-015-0632-x456087926341640 Search in Google Scholar

35. Rakha EA, Martin S, Lee AH, Morgan D, Pharoah PD, Hodi Z, et al. The prognostic significance of lymphovascular invasion in invasive breast carcinoma. Cancer. 2012;118(15):3670-80.10.1002/cncr.2671122180017 Search in Google Scholar

36. Rakha EA, Reis-Filho JS, Baehner F, Dabbs DJ, Decker T, Eusebi V, et al. Breast cancer prognostic classification in the molecular era: the role of histological grade. Breast Cancer Res. 2010;12(4):207.10.1186/bcr2607294963720804570 Search in Google Scholar

37. Rakha EA, Ellis IO. Breast Pathology: Problematic Issues. Grading of Invasive Carcinoma. Springer. pp 87-95. 2016.10.1007/978-3-319-28655-6_7 Search in Google Scholar

Empfohlene Artikel von Trend MD

Planen Sie Ihre Fernkonferenz mit Scienceendo